ArticleFrontiers in endocrinology2026
IGF-II, IGFBP-4, -6, and -7, and HMGB1 show changes in follicular fluid in PCOS.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Polycystic ovary syndrome (PCOS) is a multisystem endocrine and metabolic disease characterized by chronic low-grade inflammation, ovulatory dysfunction, hyperandrogenism, and insulin resistance. Chronic inflammation modifies the IGF system that regulates ovarian function and glucose metabolism. HMGB1 is an alarmin related with both inflammation and insulin sensitivity, and we previously described the increased follicular fluid concentration of HMGB1 in PCOS. This study aimed to investigate changes in IGF system protein concentrations in follicular fluid from PCOS with respect to control subjects. Methods: A total of 70 PCOS diagnosed according to the Rotterdam criteria and 70 control women were enrolled. Subjects were stratified based on BMI<25 (underweight/normal weight) or ≥25 (overweight/obese). PCOS and controls underwent induction of follicular development for IVF, and follicular fluid was collected during oocyte retrieval. IGF-I, IGF-II, IGFBP-1-7, and HMGB1 concentrations were measured in follicular fluids using specific ELISA kits. Results: IGF-II and IGFBP-4 were lower whereas IGFBP-6 and IGFBP-7 were increased in PCOS compared with controls. Instead, IGF-I and IGFBP-1, -2, and -3 were similar. IGFBP-5 was undetectable. HMGB1 was increased in PCOS. Stratification based on BMI showed that under/normal weight, PCOS women had lower IGF-II and IGFBP-4 and increased IGFBP-7 in follicular fluids compared with controls. IGFBP-2 was higher in under/normal weight controls with respect to their overweight/obese counterparts. When considering the molar ratios, IGF-II bioavailability was significantly lower in PCOS whereas IGF-I bioavailability was unchanged. IGFBP-3 correlated with IGFBP-4 in controls, and IGFBP-2 correlated with IGFBP-1 in PCOS. HMGB1 correlated with IGFBP-2 in PCOS and with IGF-I in controls. Conclusion: The reduction in IGF-II and IGFBP-4 in FF in PCOS is compatible with reduced follicular development. The changes in IGF-II, IGFBP-4, and IGFBP-7 in the under/normal weight PCOS women suggests that these changes are specific to PCOS. The correlation between HMGB1 and IGFBP2 is compatible with the increased inflammatory status in PCOS. The increase of IGFBP-6 and -7 is a novel finding that opens the way for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.